reference/4978726

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4978726

Outgoing Links

Predicate	Object
contentType	Journal Article\|Research Support, U.S. Gov't, P.H.S.
endingPage	525
issn	1096-911X 0098-1532
issueIdentifier	6
pageRange	519-525
publicationName	Medical and Pediatric Oncology
startingPage	519
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f981763870094771c6ffba560b3cdb18 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_90f8ea44cb33dc072ccfa70c77e8e1e7 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3e2755757eef7166f2b7b0ea51405415
bibliographicCitation	Karayalcin G, Behm FG, Gieser PW, Kung F, Weiner M, Tebbi CK, Ferree C, Marcus R, Constine L, Mendenhall NP, Chauvenet A, Murphy SB. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience. Med Pediatr Oncol. 1997 Dec;29(6):519–25. doi: 10.1002/(sici)1096-911x(199712)29:6<519::aid-mpo1>3.0.co;2-n. PMID: 9324338.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c847f5ebaf4591a4d5fb1f7c2c26ae11 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_409426118bff1f2b475dfd8acee458cf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c3a237d1ae02167fb3a9ad04f9357b1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c4b0d0f4a56823c6b79c0a08031a87c2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5bae19d87d2fd740a2dae4d92111d335 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_38c21fde88beccacde27b69a9a9ff11b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31d318e8bc6e901aa28cb5cc28e2d587 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ccdebb94e3ccb7d2ba8d056d29f8a97e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b6ccf78f7001f412cdd117e756d1146 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_37eb402a0ca732f907f4a42f045b5a52 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4478ea29de7d6f0aca4c5ee3102acea4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d506c755cc20ac77fe251dab2f2d4e5
date	199712
identifier	https://doi.org/10.1002/%28sici%291096-911x%28199712%2929:6%3C519::aid-mpo1%3E3.0.co%3B2-n https://pubmed.ncbi.nlm.nih.gov/9324338
isPartOf	https://portal.issn.org/resource/ISSN/0098-1532 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5644 https://portal.issn.org/resource/ISSN/1096-911X
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006689Q000532 http://id.nlm.nih.gov/mesh/D006689Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D002675 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D012074 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D006689Q000473 http://id.nlm.nih.gov/mesh/D003131 http://id.nlm.nih.gov/mesh/D002986 http://id.nlm.nih.gov/mesh/D002648 http://id.nlm.nih.gov/mesh/D005260
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9899 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8390 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8035 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_da97278adff984bcfd26b0237a79aba8 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_859823af5c57327aca23837367e56090 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_4d9f37351332d6afa4c0ef184fcd1773 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_416f5bbc7027f948b5d05904b7022092 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f0b53b2da041fca49ef0b9839060b345

Showing number of triples: 1 to 58 of 58.